Replies to post #481380 on Anavex Life Sciences Corp (AVXL)

[sab63090]

Investor2014

You always come through and take on questions with reasonable answers for me!

Looking at answers from people who are not debating but just using EMOJI's is not convincing to me!

I'm with you on providing full scientific data and distrusting a CEO who is doing things in such a secretive manner and is not trustworthy...however, I am hopeful that those on his team are changing him. He has kept several promises which is a change.

I have to other ways to trade stocks because of my past career experiences, so I can accept that you don't agree...ok with me!

[pcguy]

Co-primay is an adjective and is neither singular or plural. In this case co-primary describes endpoints. A "co-primary" endpoint and a "key secondary" endpoint are plural when described together. While not improper, it would have been more clear to state: Both a co-primary endpoint and key secondary endpoint. By the trial design, it was still successful, either way.

[rayovac812]

We never initially were provided with the ADL result and instead some Odds Ratio meaningless nonsense that the company has now abandoned and rightly so accepted that ADL was not significant.

You still want to make this about what AVXL did? The FDA's guidance to use ADL as an endpoint, is odds ratio's nonsensical equal. It should not have been in an early AD trial, as the likelihood that there would be changes in either the drug or placebo group, were too low. The only reason it is a topic, is because the guidance hasn't changed yet. It is the FDA on a learning curve. That change will happen, among other changes, of this I am mostly certain. Investors are good at reading tea leaves, especially the obvious ones.

This is an early AD drug candidate. We know because it has been repeatedly amplified.